RU2481842C2 - Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций - Google Patents
Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций Download PDFInfo
- Publication number
- RU2481842C2 RU2481842C2 RU2010141542/15A RU2010141542A RU2481842C2 RU 2481842 C2 RU2481842 C2 RU 2481842C2 RU 2010141542/15 A RU2010141542/15 A RU 2010141542/15A RU 2010141542 A RU2010141542 A RU 2010141542A RU 2481842 C2 RU2481842 C2 RU 2481842C2
- Authority
- RU
- Russia
- Prior art keywords
- suspension composition
- sediment
- suspension
- polysorbate
- injection
- Prior art date
Links
- 239000000725 suspension Substances 0.000 title claims abstract description 78
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 title claims abstract description 62
- 229960002117 triamcinolone acetonide Drugs 0.000 title claims abstract description 37
- 238000002347 injection Methods 0.000 title claims abstract description 32
- 239000007924 injection Substances 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 121
- 239000003814 drug Substances 0.000 claims abstract description 33
- 229940079593 drug Drugs 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 13
- 238000012800 visualization Methods 0.000 claims abstract description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 30
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 30
- 229920000053 polysorbate 80 Polymers 0.000 claims description 30
- 229940068968 polysorbate 80 Drugs 0.000 claims description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- 230000016615 flocculation Effects 0.000 claims description 20
- 238000005189 flocculation Methods 0.000 claims description 20
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 17
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 15
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 14
- 239000008215 water for injection Substances 0.000 claims description 13
- 239000006172 buffering agent Substances 0.000 claims description 11
- 150000003841 chloride salts Chemical class 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 229920001664 tyloxapol Polymers 0.000 claims description 10
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 10
- 229960004224 tyloxapol Drugs 0.000 claims description 10
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000001103 potassium chloride Substances 0.000 claims description 7
- 235000011164 potassium chloride Nutrition 0.000 claims description 7
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 6
- 210000004127 vitreous body Anatomy 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 208000001344 Macular Edema Diseases 0.000 claims description 4
- 206010025415 Macular oedema Diseases 0.000 claims description 4
- 239000007900 aqueous suspension Substances 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 201000010230 macular retinal edema Diseases 0.000 claims description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract 1
- 239000013049 sediment Substances 0.000 description 105
- 239000002245 particle Substances 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 13
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 9
- 229940063199 kenalog Drugs 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229960005294 triamcinolone Drugs 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 4
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 229950008882 polysorbate Drugs 0.000 description 3
- AYRVGWHSXIMRAB-UHFFFAOYSA-M sodium acetate trihydrate Chemical compound O.O.O.[Na+].CC([O-])=O AYRVGWHSXIMRAB-UHFFFAOYSA-M 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 208000002691 Choroiditis Diseases 0.000 description 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000003971 Posterior uveitis Diseases 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 201000011190 diabetic macular edema Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229960001005 tuberculin Drugs 0.000 description 2
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 201000011275 Epicondylitis Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 208000004760 Tenosynovitis Diseases 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 230000003311 flocculating effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000001957 retinal vein Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000023924 subacute bursitis Diseases 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001760 tenon capsule Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- -1 triamcinolone steroid Chemical class 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3545908P | 2008-03-11 | 2008-03-11 | |
| US61/035,459 | 2008-03-11 | ||
| PCT/US2009/036652 WO2009114521A1 (en) | 2008-03-11 | 2009-03-10 | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010141542A RU2010141542A (ru) | 2012-04-20 |
| RU2481842C2 true RU2481842C2 (ru) | 2013-05-20 |
Family
ID=40548758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010141542/15A RU2481842C2 (ru) | 2008-03-11 | 2009-03-10 | Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8128960B2 (enExample) |
| EP (1) | EP2262506B1 (enExample) |
| JP (1) | JP5581227B2 (enExample) |
| KR (1) | KR101555293B1 (enExample) |
| CN (1) | CN101959519B (enExample) |
| AR (1) | AR070824A1 (enExample) |
| AU (1) | AU2009223649B2 (enExample) |
| BR (1) | BRPI0909630B8 (enExample) |
| CA (1) | CA2717605C (enExample) |
| CL (1) | CL2009000573A1 (enExample) |
| DK (1) | DK2262506T3 (enExample) |
| ES (1) | ES2471122T3 (enExample) |
| MX (1) | MX2010009974A (enExample) |
| PL (1) | PL2262506T3 (enExample) |
| PT (1) | PT2262506E (enExample) |
| RU (1) | RU2481842C2 (enExample) |
| SI (1) | SI2262506T1 (enExample) |
| TW (1) | TWI468165B (enExample) |
| UY (1) | UY31699A1 (enExample) |
| WO (1) | WO2009114521A1 (enExample) |
| ZA (1) | ZA201005839B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| RU2481842C2 (ru) * | 2008-03-11 | 2013-05-20 | Алькон Рисерч, Лтд. | Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций |
| KR20110099044A (ko) * | 2008-12-22 | 2011-09-05 | 알콘 리서치, 리미티드 | 후안부에 유효농도의 활성제를 전달하기 위한 국소 안용액 조성물 |
| WO2012051575A2 (en) | 2010-10-15 | 2012-04-19 | Iscience Interventional Corporation | Device for ocular access |
| CN102008488B (zh) * | 2010-11-24 | 2012-10-10 | 广州固志医药科技有限公司 | 一种曲安奈德眼用制剂及其制备方法 |
| AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| AU2013342275B2 (en) * | 2012-11-08 | 2017-11-09 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| SG10201702674PA (en) | 2013-05-03 | 2017-06-29 | Clearside Biomedical Inc | Apparatus and methods for ocular injection |
| WO2014197317A1 (en) | 2013-06-03 | 2014-12-11 | Clearside Biomedical, Inc. | Apparatus and methods for drug delivery using multiple reservoirs |
| WO2015196085A2 (en) | 2014-06-20 | 2015-12-23 | Clearside Biomedical, Inc. | Variable diameter cannula and methods for controlling insertion depth for medicament delivery |
| US9694145B1 (en) | 2016-03-29 | 2017-07-04 | Joseph Onorato | Auto-injector systems and method for delivering cyst medication on demand |
| JP2019514581A (ja) | 2016-05-02 | 2019-06-06 | クリアサイド バイオメディカル，インコーポレイテッド | 眼の薬物送達のためのシステムおよび方法 |
| US10973681B2 (en) | 2016-08-12 | 2021-04-13 | Clearside Biomedical, Inc. | Devices and methods for adjusting the insertion depth of a needle for medicament delivery |
| WO2018204515A1 (en) | 2017-05-02 | 2018-11-08 | Georgia Tech Research Corporation | Targeted drug delivery methods using a microneedle |
| WO2019136512A1 (en) * | 2018-01-10 | 2019-07-18 | Eye Co Pty Ltd | Medical device and pharmaceutical composition for treatment of an eye disease or condition |
| USD893715S1 (en) | 2018-11-06 | 2020-08-18 | Joseph Onorato | Measurement guide for a cyst, lesion or skin disorder |
| CA3136814A1 (en) * | 2019-04-16 | 2020-10-22 | Clearside Biomedical, Inc. | Injectable triamcinolone formulations |
| US10814001B1 (en) | 2019-05-06 | 2020-10-27 | Rvl Pharmaceuticals, Inc. | Oxymetazoline compositions |
| CN114010593A (zh) * | 2021-11-23 | 2022-02-08 | 莱默(北京)药业科技有限公司 | 一种曲安奈德混悬注射液及制备方法 |
| CN115969784B (zh) * | 2022-12-26 | 2025-10-21 | 昆明积大制药股份有限公司 | 曲安奈德注射液的制备方法 |
| WO2025114562A1 (en) * | 2023-11-30 | 2025-06-05 | Institut National de la Santé et de la Recherche Médicale | Intravitreal spironolactone suspension |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050065137A1 (en) * | 2003-09-23 | 2005-03-24 | Alcon, Inc. | Triamcinolone acetonide and anecortave acetate formulations for injection |
| US20070020336A1 (en) * | 2005-07-22 | 2007-01-25 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
| RU2300379C2 (ru) * | 2001-07-09 | 2007-06-10 | Комбинаторкс, Инкорпорейтед | Комбинации для лечения воспалительных заболеваний |
| EP1867334A1 (en) * | 2005-02-18 | 2007-12-19 | Santen Pharmaceutical Co., Ltd. | Method of relieving or avoiding side effect of steroid compound |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3962430A (en) * | 1974-08-07 | 1976-06-08 | Merck & Co., Inc. | Sterilization of solid non-electrolyte medicinal agents employing sodium chloride |
| US4370325A (en) * | 1979-03-30 | 1983-01-25 | Dermik Laboratories | Pharmaceutical compositions and method of treatment |
| US4432964A (en) * | 1981-08-24 | 1984-02-21 | Alza Corporation | Topical composition containing steroid in two forms released independently from polymeric carrier |
| US5164190A (en) * | 1990-12-11 | 1992-11-17 | Theratech, Inc. | Subsaturated transdermal drug delivery device exhibiting enhanced drug flux |
| WO1995003807A1 (en) | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
| AU4472396A (en) | 1994-12-30 | 1996-07-24 | American Home Products Corporation | Clear non-alcoholic hydrocortisone solutions |
| CA2336703A1 (en) | 1998-07-10 | 2000-01-20 | The University Of Sydney | Prophylactic treatments of neovascularisation in macular degeneration |
| AR026073A1 (es) | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica acuosa que contiene ciclesonida |
| AUPQ496500A0 (en) | 2000-01-06 | 2000-02-03 | University Of Sydney, The | Kit |
| US6395294B1 (en) | 2000-01-13 | 2002-05-28 | Gholam A. Peyman | Method of visualization of the vitreous during vitrectomy |
| US6656505B2 (en) * | 2000-07-21 | 2003-12-02 | Alpharma Uspd Inc. | Method for forming an aqueous flocculated suspension |
| JP5000835B2 (ja) * | 2000-08-25 | 2012-08-15 | 千寿製薬株式会社 | 水性懸濁液剤 |
| US20030129242A1 (en) | 2002-01-04 | 2003-07-10 | Bosch H. William | Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
| RU2005129276A (ru) * | 2003-02-20 | 2006-01-27 | Алькон, Инк. (Ch) | Применение стероидов для лечения субъектов, страдающих заболеванием глаз |
| US20040186084A1 (en) | 2003-03-21 | 2004-09-23 | Akorn, Inc. | Triamcinolone formulations and methods for their preparation and use |
| US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| US20060141049A1 (en) | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
| JP2007516297A (ja) * | 2003-12-23 | 2007-06-21 | アルザ・コーポレーシヨン | 制御送達用薬剤組成物の溶解度を高くする方法および投薬形態物 |
| EP1706095B1 (en) | 2004-01-20 | 2008-12-24 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
| US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US20070225727A1 (en) | 2004-05-31 | 2007-09-27 | Keiichi Matsuhisa | Transparent Tissue-Visualizng Preparation |
| US20060089590A1 (en) | 2004-10-27 | 2006-04-27 | John Higuchi | Methods and devices for sustained in-vivo release of an active agent |
| US20080008762A1 (en) | 2004-11-17 | 2008-01-10 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Steroid Formulation And Methods Of Treatment Using Same |
| ITRM20050547A1 (it) | 2005-11-04 | 2007-05-05 | Sooft Italia S R L | Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico. |
| RU2481842C2 (ru) * | 2008-03-11 | 2013-05-20 | Алькон Рисерч, Лтд. | Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций |
-
2009
- 2009-03-10 RU RU2010141542/15A patent/RU2481842C2/ru active
- 2009-03-10 ES ES09720520.7T patent/ES2471122T3/es active Active
- 2009-03-10 DK DK09720520.7T patent/DK2262506T3/da active
- 2009-03-10 SI SI200930950T patent/SI2262506T1/sl unknown
- 2009-03-10 EP EP09720520.7A patent/EP2262506B1/en active Active
- 2009-03-10 TW TW98107670A patent/TWI468165B/zh active
- 2009-03-10 WO PCT/US2009/036652 patent/WO2009114521A1/en not_active Ceased
- 2009-03-10 PL PL09720520T patent/PL2262506T3/pl unknown
- 2009-03-10 AU AU2009223649A patent/AU2009223649B2/en active Active
- 2009-03-10 CN CN2009801076823A patent/CN101959519B/zh active Active
- 2009-03-10 CA CA2717605A patent/CA2717605C/en active Active
- 2009-03-10 US US12/401,168 patent/US8128960B2/en active Active
- 2009-03-10 PT PT97205207T patent/PT2262506E/pt unknown
- 2009-03-10 MX MX2010009974A patent/MX2010009974A/es active IP Right Grant
- 2009-03-10 UY UY31699A patent/UY31699A1/es not_active Application Discontinuation
- 2009-03-10 KR KR1020107022609A patent/KR101555293B1/ko active Active
- 2009-03-10 BR BRPI0909630A patent/BRPI0909630B8/pt active IP Right Grant
- 2009-03-10 JP JP2010550813A patent/JP5581227B2/ja active Active
- 2009-03-11 AR ARP090100862A patent/AR070824A1/es unknown
- 2009-03-11 CL CL2009000573A patent/CL2009000573A1/es unknown
-
2010
- 2010-08-16 ZA ZA2010/05839A patent/ZA201005839B/en unknown
-
2012
- 2012-01-17 US US13/352,043 patent/US20120115829A1/en not_active Abandoned
- 2012-01-17 US US13/352,009 patent/US8211880B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2300379C2 (ru) * | 2001-07-09 | 2007-06-10 | Комбинаторкс, Инкорпорейтед | Комбинации для лечения воспалительных заболеваний |
| US20050065137A1 (en) * | 2003-09-23 | 2005-03-24 | Alcon, Inc. | Triamcinolone acetonide and anecortave acetate formulations for injection |
| WO2005032510A1 (en) * | 2003-09-23 | 2005-04-14 | Alcon, Inc. | Triamcinolone acetonide and anecortave acetate formulations for injection |
| EP1867334A1 (en) * | 2005-02-18 | 2007-12-19 | Santen Pharmaceutical Co., Ltd. | Method of relieving or avoiding side effect of steroid compound |
| US20070020336A1 (en) * | 2005-07-22 | 2007-01-25 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8211880B2 (en) | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection | |
| JP7293412B2 (ja) | 注射製剤 | |
| Madan et al. | In situ forming polymeric drug delivery systems | |
| JP6894436B2 (ja) | 徐放性シクロスポリン添加微粒子 | |
| US20050065137A1 (en) | Triamcinolone acetonide and anecortave acetate formulations for injection | |
| CN101810563B (zh) | 他克莫司眼用在体凝胶制剂及其制备方法 | |
| KR102888598B1 (ko) | 약물 전달을 위한 약학적 생분해성 겔 | |
| CN111107838B (zh) | 用于治疗干眼症的含有瑞巴派特的滴眼剂组合物及其增溶和稳定化方法 | |
| WO2016036588A1 (en) | Pharmaceutical suspensions containing etoricoxib | |
| CN113797163B (zh) | 一种滴眼给药防治干性黄斑病变和视网膜光损伤的眼用制剂 | |
| CN104721130B (zh) | 一种布林佐胺包合物眼用制剂及其制备方法 | |
| JPH04501563A (ja) | 水溶性イボパミン酸付加塩を含有する眼薬 | |
| HK1146464B (en) | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection | |
| WO2022195382A1 (en) | A stable ophthalmic nanosupension of brinzolamide | |
| CN101366701A (zh) | N，n-二甲基甘氨酸-2，6-二异丙基苯酯盐类注射剂 | |
| BR112018012201B1 (pt) | Micropartículas carregadas com ciclosporina de liberação sustentada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC43 | Official registration of the transfer of the exclusive right without contract for inventions |
Effective date: 20200429 |
|
| PC41 | Official registration of the transfer of exclusive right |
Effective date: 20201012 |